bluebird bio starts treatment in Phase I trial for multiple myeloma

bluebird bio has started treating patients in a Phase I clinical trial (CRB-402) of its investigational candidate bb21217 for relapsed or refractory multiple myeloma.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news